Background: We recently demonstrated that the procoagulant activity of skeletal muscle myosin (SkM) involved the binding of coagulation factor (F) XI to enhance FXI activation by thrombin. However, the impact of SkM on the enzymatic activities of activated FXI (FXIa) remains unclear. Aims: Determine the influence of SkM interactions on the expression of FXIa activities. Methods: Binding studies between FXIa and SkM were conducted using biolayer interferometry (BLI). Kallikrein, a FXIa homolog, served as a negative control. The interactions between SkM and FXIa were investigated through fluorescence spectroscopy using dansyl-labeled FXIa. Chromogenic assays for FXIIa were employed to measure FXII activation by FXIa. Tissue factor pathway inhibitor (TFPI) inactivation by FXIa was assessed by determining FXa inhibition by TFPI using FX chromogenic assays. Quantification of complement factor H (CFH) cleavage by FXIa as well as FV activation by FXIa were carried out using SDS PAGE and Coomassie blue staining. Results: BLI data showed that SkM exhibited a high binding affinity for FXIa with a dissociation constant of 1.6 nM, whereas SkM did not bind kallikrein. The addition of SkM induced a 9 nm shift in the emission spectrum of dansyl-labeled FXIa. The presence of SkM increased the rate of feedback FXII activation by FXIa but not by kallikrein. The addition of SkM inhibitors, trifluoperazine and blebbistatin, reduced the enhancement effect of SkM on the ability of FXIa to activate FXII. Furthermore, SkM increased the rate of enzymatic inactivation of TFPI by FXIa, the rate of cleavage of CFH by FXIa, and the rate of activation of FV by FXIa. Conclusions: SkM binds with high affinity to FXIa and serves as a co-factor to enhance multiple different enzymatic activities of FXIa. Future work is needed to examine the multiple procoagulant activities of SkM in the setting of hemostasis and acute trauma.